Nucleome Therapeutics
is a Private company. Mark Bodmer is the CEO of Nucleome Therapeutics. Nucleome Therapeutics has received a total of $42.5M in funding. Nucleome Therapeutics has 2 followers on Owler.Nucleome Therapeutics
is a Private company. Mark Bodmer is the CEO of Nucleome Therapeutics. Nucleome Therapeutics has received a total of $42.5M in funding. Nucleome Therapeutics has 2 followers on Owler.
News
Jul 14, 2026
Manufacturing Chemist
Nucleome Therapeutics: Nucleome Therapeutics secures US patent for Micro Capture-C 3D genomics technology
Jan 07, 2026
StreetInsider
Press Release: Nucleome Therapeutics : Nucleome Therapeutics nominates first preclinical development candidate
Nov 06, 2025
FinanzNachrichten
Nucleome Therapeutics: Nucleome Therapeutics founder Professor James Davies and Oxford University publish paper in prestigious journal Cell
Oct 08, 2024
Benzinga
Nucleome Therapeutics: ROME Therapeutics, Enara Bio, Nucleome Therapeutics and NYU Langone Health to Host 3rd Annual Dark Genome Symposium
Jul 16, 2024
The Pharma Letter
Nucleome Therapeutics: Mark Bodmer takes top job at Nucleome
Nov 01, 2023
GlobalNewswire
Press Release: Nucleome Therapeutics : Enara Bio, ROME Therapeutics and Nucleome Therapeutics to Host 2nd Annual Dark Genome Symposium
Oct 20, 2022
UK Tech News
Nucleome Therapeutics: Startup using machine learning to find new medicines raises 38m
Oct 19, 2022
BioSpace
Nucleome Therapeutics: Pfizer, Merck and J&J Back UK Startup Mining the Dark Genome for Autoimmune Therapies
Oct 19, 2022
Endpoints News
Nucleome Therapeutics: Drug discovery biotech looking into the 'dark' regions of the human genome picks up a $40M+ Series A
Apr 28, 2022
Business and Innovation Magazine
Nucleome Therapeutics: Nucleome Therapeutics appoints Phil Boyd as Chief Financial Officer